Supernus Pharmaceuticals reported $62.22M in Selling and Administration Expenses for its fiscal quarter ending in June of 2025.


Selling And Administration Expenses Change Date
Abbott USD 3.09B 39M Jun/2025
ANI Pharmaceuticals USD 81.77M 5.24M Jun/2025
Aurora Cannabis CAD 45.63M 7.45M Jun/2025
Bristol-Myers Squibb USD 1.71B 129M Jun/2025
Canopy Growth CAD 40.12M 504K Jun/2025
Corcept Therapeutics USD 103.85M 13.19M Jun/2025
Eisai JPY 100.16B 6.34B Jun/2025
Eli Lilly USD 2.75B 390.8M Jun/2025
Novo Nordisk 18.85B 2.74B Jun/2025
Pacira USD 77.19M 9.58M Jun/2025
Perrigo USD 273.1M 8.1M Jun/2025
Pfizer USD 3.42B 406M Jun/2025
Supernus Pharmaceuticals USD 62.22M 27.72M Jun/2025
United Therapeutics USD 212.5M 42.4M Jun/2025
Xeris Pharmaceuticals USD 44.39M 35.89M Jun/2025